Application of CDK4/6 Inhibitors in Premenopausal Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: a Real-World Experience

被引：0

作者：

Kurbacher, Christian M. ^{[1
]}

Fischer, Lotta Ada ^{[2
]}

Heinrich, Georg ^{[3
]}

Herz, Susanne ^{[1
]}

Schott, Alexander ^{[1
]}

Kurbacher, A. Tabea ^{[1
]}

Kurbacher, Jutta Anna ^{[4
]}

Rudlowski, Christian ^{[5
]}

Warm, Mathias R. ^{[2
]}

机构：

[1] Gynakol Zentrum Bonn Friedenspl, Gynakol Schwerpunkt Gynakol Onkol 1, Bonn, Germany

[2] Stadt Klinikum Holweide, Brustzentrum, Cologne, Germany

[3] Praxis Gynakol Onkol, Furstenwalde, Germany

[4] Gynakol Zentrum Bonn Friedenspl, Gynakol Allgemeine Gynakol & Geburtshilfe 2, Bonn, Germany

[5] Evangel Krankenhaus Bergisch Gladbach, Frauenklin, Bergisch Gladbach, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

552

引用

页码：19 / 19

页数：1

共 50 条

[1] TREATMENT OF PREMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WITH AN CDK4/6 INHIBITOR COMBINED WITH ENDOCRINE AGENTS: A REAL-WORLD EXPERIENCE
Kurbacher, Christian Martin
Fischer, Lotta Ada
Heinrich, Georg
Warm, Mathias
Schott, Alexander
Kurbacher, A. Tabea
Kurbacher, Jutta Anna
Rudlowski, Christian
BREAST, 2019, 48 : S55 - S56
[2] Disparities in receipt of CDK4/6 inhibitors with endocrine therapy as therapy for hormone receptor-positive, HER2-negative metastatic breast cancer in the real-world setting
Kimmick, G.
Pilehvari, A.
You, W.
Bonilla, G.
Anderson, R.
ANNALS OF ONCOLOGY, 2023, 34 : S373 - S373
[3] CDK4/6-Inhibitors Inclusion in the Treatment of metastatic Hormone Receptor-positive, HER2-negative Breast Cancer
Forstmeyer, D.
ONKOLOGE, 2016, 22 (07): : 507 - 508
[4] CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
Matutino, Adriana
Amaro, Carla
Verma, Sunil
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
[5] CDK4/6 inhibitors for hormone receptor-positive HER2-negative metastatic breast cancer: does one size fit all?
Fedele, Palma
Cinieri, Saverio
FUTURE MEDICINAL CHEMISTRY, 2019, 11 (11) : 1237 - 1239
[6] Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
Pla, Helena
Felip, Eudald
Obadia, Veronica
Pernas, Sonia
Vinas, Gemma
Margeli, Mireia
Fort-Culillas, Roser
Del Barco, Sonia
Sabate, Nuria
Fort, Eduard
Lezcano, Clara
Cirauqui, Beatriz
Quiroga, Vanesa
Stradella, Agostina
Gil, Miguel Gil
Esteve, Anna
Recalde, Sabela
CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (07): : 1748 - 1758
[7] Clinical efficacy of everolimus and CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer by treatment sequence
Jeong, J. H.
Jeong, H.
Kim, J. E.
Ahn, J-H.
Jung, K. H.
Kim, S-B.
ANNALS OF ONCOLOGY, 2021, 32 : S72 - S73
[8] The Mutational Landscape of 1172 Patients with Hormone Receptor-Positive, HER2-negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors
Shah, Ami N.
Lim, Bora
Mita, Monica M.
Mauer, Elizabeth
Layng, Kayla V.
Chao, Calvin
Brufsky, Adam M.
CANCER RESEARCH, 2023, 83 (05)
[9] Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study
Fedele, Palma
Landriscina, Matteo
Moraca, Lucia
Cusmai, Antonio
Gnoni, Antonio
Licchetta, Antonella
Guarini, Chiara
Lanotte, Laura
Pappagallo, Maria Nicla
Melaccio, Assunta
Giordano, Guido
Maselli, Felicia Maria
Pinto, Antonello
Giuliani, Francesco
Chiuri, Vincenzo
Giotta, Francesco
Gadaleta-Caldarola, Gennaro
CANCERS, 2024, 16 (20)
[10] Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population
Chen, Bo-Fang
Tsai, Yi-Fang
Chao, Ta-Chung
Lien, Pei-Ju
Lin, Yen-Shu
Feng, Chin-Jung
Chen, Yen-Jen
Cheng, Han-Fang
Liu, Chun-Yu
Lai, Jiun-, I
Tseng, Ling-Ming
Huang, Chi-Cheng
CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)

← 1 2 3 4 5 →